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whereas adhesion of PBMC increased significantly, as de-
scribed by other papers. In summary, neither calcineurin in-
hibitors nor mTOR inhibitors activate human micro- and 
macrovascular EC. Therefore, the investigated drugs are un-
likely to contribute to EC activation during transplant-associ-
ated vasculopathy.  Copyright © 2008 S. Karger AG, Basel 
 Introduction 
 Endothelial cell (EC) dysfunction/activation is a prom-
inent feature in several diseases ranging from atheroscle-
rosis to transplant rejection. These processes lead to rap-
id and transient upregulation of proinflammatory mol-
ecules, such as adhesion molecules. The expression of 
E-selectin, vascular and intracellular adhesion molecules 
(VCAM-1, ICAM-1) in capillaries, and the levels of their 
soluble forms, correlate with the severity of cellular and 
humoral rejection  [1, 2] , and may eventually influence 
patient and graft survival  [3] . Endothelial activation and 
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 Abstract 
 We examined the effect of cyclosporin A, tacrolimus, siroli-
mus and everolimus on the cell growth, viability, prolifera-
tion, expression of cellular adhesion molecules (CAM) and 
leukocyte (PBMC) binding of human macrovascular (coro-
nary artery, saphenous vein) and microvascular endothelial 
cells (EC). Tacrolimus did not affect EC integrity, growth or 
expression of CAM. Exclusively, EC from the coronary arteries 
showed a reduced cellular growth (about 30%) under cyclo-
sporin A and tacrolimus treatment. In contrast, treatment 
with mTOR inhibitors reduced EC proliferative activity by 
about 40%, independently of the EC origin. No induction of 
apoptosis (caspase-3/7 activity) or cytotoxicity (MTS test) 
was observed. Long-term treatment with high concentra-
tions of sirolimus and everolimus did not enhance the ex-
pression of CAM. Stimulation with tumor necrosis factor sig-
nificantly increased the expression of CAM, independently 
of the drugs used. None of the mTOR inhibitors influenced 
the tumor necrosis factor-induced expression of CAM, 
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allograft survival have been greatly improved by multiple 
immunosuppressive drugs  [4] .
 The impact of immunosuppression on individual en-
dothelial properties has been investigated in several in 
vitro models  [5–7] . However, most of these studies used 
human umbilical veins, immortalized or animal-derived 
EC often without considering the functional heterogene-
ity of EC derived from different origins  [8, 9] . The objec-
tive of our study was to elucidate the direct impact of 
mTOR inhibitors (mammalian target of rapamycin) and 
calcineurin inhibitors (CNI) on EC derived from micro- 
and macrovascular origins. mTOR inhibitors are impor-
tant immunosuppressive drugs that exert synergistic im-
munomodulatory effects when administered together 
with CNI as they lead to a sequential blockade of IL-2-
mediated pathways: CNI lead to a decreased production 
of IL-2 and mTOR inhibitors block IL-2-activated mTOR 
signal transduction. Furthermore, a combined regimen 
of CNI and mTOR inhibitor treatment with dose tapering 
of the CNI seems to be a clinically efficient strategy, al-
though there is still a lack of data focusing on their effects 
at specific sites of action. Therefore, we focused on these 
2 drug classes. A particular ex vivo – in vitro model using 
patient-derived EC cultures was applied to closely mimic 
the in vivo situation of atherosclerotic vessels during the 
early postoperative period after transplantation with in-
cipient immunosuppression.
 Methods 
 Cell Culture 
 Patient-derived saphenous vein EC (HSVEC) and coronary 
artery EC (HCAEC) were isolated from patients undergoing cor-
onary artery bypass surgery and orthotopic heart transplanta-
tion. Adult dermal EC, cardiac microvascular EC (HMVEC) and 
HCAEC were purchased from Cambrex (Walkersville, Md., USA) 
and Promocell (Heidelberg, Germany). All experiments were ap-
proved by the local ethics committee and conducted in accor-
dance with the Declaration of Helsinki. EC cultures were culti-
vated in endothelial-specific medium (EGM-kit; Cat. No. C-
22010, Promocell) supplemented with 30% pooled human serum 
(culture medium with serum; CMS) according to Lehle et al.  [10] . 
These culture conditions are essential for optimal growth of pa-
tient-derived EC in the indicated experimental time frame. The 
purity of the preparations was 99%, as monitored by staining with 
an anti-human CD31-PE antibody (Ancell, Bayport, Minn., USA), 
and flow-cytometric analysis (FACSCalibur, BD Biosciences, San 
Jose, Calif., USA). EC from passages 3–5 were seeded with a den-
sity of 4,000 cells/cm 2 in 96-well plates (Costar, Pleasanton, Calif., 
USA) using 150   l of CMS per well. After 3 days, the medium was 
renewed and immunosuppressive drugs were added for 48 h un-
der standard culture conditions. In order to detect tumor necrosis 
factor (TNF)-induced expression of E-selectin, VCAM-1 and 
ICAM-1, EC were stimulated with 10 ng/ml TNF (Calbiochem, 
Bad Soden, Germany) for the last 4 h (E-selectin) and 20 h (ICAM-
1, VCAM-1) of drug treatment, respectively. In order to exclude 
any influence of the proliferative activity of untreated control 
cells, we seeded EC with a density of 30,000   cells/cm 2 in 96-well 
plates for 2 days, and incubated with each drug for 48 h as de-
scribed above. The cells in the resulting confluent monolayer 
were stable over the next 4 days. Trypan blue exclusion yielded a 
viability of about 85–95%.
 Immunosuppressive Drugs 
 Cyclosporin A (CsA) and everolimus (Eve) (Novartis Pharma, 
Nürnberg, Germany), tacrolimus (Tac; Fujisawa Healthcare, 
Deerfield, Ill., USA), and sirolimus (Sir; Wyeth-Ayerst, Madison, 
N.J., USA) were dissolved in 100% ethanol (10 m M stock solution) 
and diluted with ethanol and CMS (working concentration of the 
drug 1   M; ethanol always being 0.1%, 150   l per well). Control 
cells were incubated with CMS plus 0.1% ethanol.
 Cell Growth Characteristics 
 To determine cell numbers and dimensions, EC were treated 
as described above, detached by collagenase type 2 (Roche Diag-
nostics, Basel, Switzerland) treatment and cell suspensions were 
counted using an automated cell analyzer system allowing both 
the discrimination of viable cells from dead cells/debris and the 
determination of average cell volumes (CASY1; Schärfe-System, 
Reutlingen, Germany). Cell counts were recorded after 48 h of 
drug exposure and documented in relation to respective untreat-
ed controls (100%) at the corresponding time points.
 Cell Viability, Mitochondrial Activity and Apoptosis 
 The metabolic status of EC in culture was determined using 
the tetrazolium-based mitochondrial dehydrogenase assay (MTS; 
Promega, Madison, Wisc., USA) according to manufacturer’s in-
structions. EC were incubated with or without immunosuppres-
sive drugs for 47 h in CMS, which was then replaced by medium 
(without additives) supplemented with 16% MTS solution and in-
cubated for 1 h under standard culture conditions. Absorbance 
was measured at 490 nm with a 96-well-plate reader (MWG-Bio-
tech, Ebersberg, Germany) and cellular absorbance was calcu-
lated by dividing absorbance per well by cell counts per well.
 Apoptosis was determined in cultures (drug treated and un-
treated) via the activation of caspases-3/7 (Promega) following 
manufacturer’s instructions. After exhausting the supernatants, 
EC were lysed by addition of a lysis buffer (including caspase-3/7 
substrate) and frozen overnight at –20 ° C. Caspase activity was 
expressed as fluorescence per counted cell. Incubation with 10 
  M staurosporine (Sigma, St. Louis, Mo., USA) for 4 h was used 
as a positive control.
 Simultaneously, experimental series were assayed microscop-
ically for cell viability using the trypan blue exclusion tech-
nique.
 Proliferative Activity 
 Proliferative activity was assessed using 2 techniques:
 (1) [Methyl- 3 H]-thymidine incorporation: [Methyl- 3 H]-thy-
midine 0.1   Ci (Amersham Pharmacia, Buckinghamshire, UK) 
was added per well during the last 24 h of the 48-hour drug incu-
bation period. Cells were dissociated with 2.5% trypsin/1% EDTA 
(BioWhittaker, Waldersville, Md., USA) and harvested on glass-
 mTOR and Calcineurin Inhibitors and 
Endothelial CAM Expression 
J Vasc Res 2008;45:333–342 335
fiber membranes (Filtermat B; Wallac, Turku, Finland) using a 
semiautomatic cell harvester (Inotech, Nabburg, Germany). In-
corporated radioactive [methyl- 3 H]-thymidine was measured in 
corrected counts per minute (ccpm) per well and documented rel-
ative to respective untreated controls.
 (2) Flow-cytometric univariant DNA analysis was performed 
to validate changes in [methyl- 3 H]-thymidine incorporation of 
mTOR-inhibitor-exposed EC. EC were grown in T75 culture 
flasks (4,000 cells/cm 2 , 12 ml CMS). At day 4 (80% confluence), 
the medium was renewed and supplemented with or without 
mTOR inhibitors (10   M). After 24 h of incubation, cells were 
harvested by collagenase digestion, washed twice in PBS/0.2% 
BSA and fixed in 70% methanol (Merck, Darmstadt, Germany) at 
4 ° C overnight (1  ! 10 6  cells/ml). For propidium-iodide staining, 
cell suspensions were again washed, pre-incubated with 10 U/ml 
RNAse (Sigma) (37 ° C, 20 min), and propidium iodide was added 
(50   g/ml, 15–30 min). DNA histograms were recorded using a 
FACSCalibur flow cytometer. High-quality cell cycle analysis was 
performed with the WinCycle software package (Phoenix Flow 
Systems, San Diego, Calif., USA).
 Expression of Cellular Adhesion Molecules 
 Drug-treated and untreated EC monolayers in 96-well plates 
were washed with pre-warmed PBS, fixed with methanol/acetone 
(1: 1, –20 ° C, 10 min), and stored at –20 ° C to determine cellular 
amounts of VCAM-1, ICAM-1 and E-selectin using a cellular 
ELISA  [10] . In a separate experimental setup, the cell count was 
analyzed under identical culture conditions using CASY1. The 
expression of cellular adhesion molecules (CAM) was defined as 
the ratio of absorbance per culture area (0.3 cm 2 ) and the cell 
count of the respective sample. The activation factor (AF) defines 
the proportions of TNF-stimulated expression and basal expres-
sion.
 For histological analysis, EC were grown on chamber slides 
(Nunc, Roskilde, Denmark) up to confluence, treated with TNF 
or culture medium for 4 h, washed with PBS, fixed in acetone/
methanol (1: 1) for 10 min at –20 ° C and labeled using an FITC-
conjugated monoclonal anti-human CD62E (E-selectin) antibody 
(Dianova, Hamburg, Germany).
 Adhesion of Peripheral Blood Mononuclear Cells 
 Peripheral blood mononuclear cells (PBMC) were separated 
from EDTA peripheral blood of healthy volunteers by Ficoll-
Paque density gradient centrifugation (density: 1.077 g/ml,
Amersham Biosciences, Uppsala, Sweden) and washed in PBS. 
PBMC (1  ! 10 7 cells/ml) were stained with Calcein-AM (5   M, 
15 min, 37 ° C; Molecular Probes, Eugene, Oreg., USA), washed 
twice with PBS, centrifuged at 400  g (10 min, room temperature), 
and resuspended in PBS (2  ! 10 7 PBMC/ml). The ratio of the 
number of stained PBMC and respective fluorescence was calcu-
lated to quantify the number of adherent PBMC (standard curve). 
The adhesion assay was performed as previously described by De 
Clerck et al.  [11] . EC were cultivated in 96-well microtiter plates 
and incubated with immunosuppressive drugs as described above. 
For the last 4 h of incubation with drugs, EC were treated with 10 
ng/ml TNF or PBS as a control. Afterwards, EC were washed with 
pre-warmed CMS and incubated with 1.2  ! 10 5 labeled PBMC 
per well at 37 ° C for 30 min. Nonadherent PBMC in the superna-
tant were removed by washing 3 times. The fluorescence of the 
adherent PBMC was measured (excitation 485 nm, emission 535 
nm). In a separate set of experiments, the number of EC were mea-
sured with CASY1 and the ratio of adherent PBMC (via standard 
curve) to EC was determined.
 Statistics 
 Data are given as mean (quadruplicate samples for each cul-
ture)  8 SD. Wilcoxon signed rank test was used to verify differ-
ences between drug-treated and untreated control cells. Most pa-
rameters were documented in relation to respective untreated 
controls. The effect of different drugs on EC was analyzed using 
the Mann-Whitney rank sum test. Statistical significance was 
considered to be p  ! 0.05. p  ! 0.01 was considered to be highly 
significant; results are marked with 1 or 2 asterisks within the 
graphs, respectively.
 Results 
 Impact of Immunosuppressive Drugs on EC Viability 
and Proliferation 
 High concentrations of Tac (1   M) did not affect viabil-
ity (trypan blue staining, MTS test) and absolute cell count 
in the monolayers of micro- and macrovascular EC. How-
ever, the incorporation of [methyl- 3 H]-thymidine was re-
duced for HCAEC. Reduction of the drug concentra-
tion in the culture medium (0.1–100 n M ) did not influence 
the amount of EC in the monolayer compared to untreat-
ed control cells (data not shown). At the same concentra-
tion CsA did not influence cell growth of HSVEC and 
HMVEC. However, HCAEC showed a higher sensitivity 
to this CNI. Compared to untreated control cells, incuba-
tion with 1   M CsA reduced cell counts significantly by 
about 20–30% ( fig. 1 ). The effect was verified by measur-
ing the incorporation of [methyl- 3 H]-thymidine (not sig-
nificant,  fig. 1 ). The mitochondrial activity per remaining 
cell (MTS reaction) was not influenced by drug treatment 
(data not shown). The effect of CsA on the cell growth of 
HCAEC was dose dependent. Thus, incubation of HCAEC 
with low and therapeutic concentrations of CsA (0.1–100 
n M ) did not affect the cell count in the monolayer (data 
not shown). In addition, in a preliminary experiment we 
showed that the time to reach the maximum drug effect 
was more than 36 h (t1/2 being 29–30 h, t1/2 reflecting the 
time at which half maximal inhibition of cell growth was 
attained). Therefore, we fixed an experimental time of 
48 h, as mentioned above. High concentrations (1   M) of 
Sir and Eve delayed cell growth. After 48 h of treatment 
the cell density was about 40% lower than untreated con-
trols (HSVEC: p  ! 0.01; HCAEC and HMVEC: p  ! 0.05; 
 fig. 1 a). Furthermore, drug exposure did not systemati-
cally modify EC volume (e.g. HSVEC: untreated controls: 
4,360  8 545 fl; CsA: 4,520  8 765 fl; Tac: 4,250  8 695 fl; 
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Sir: 3,895  8 570 fl; Eve: 3,980  8 580 fl). Reduced
cell growth in cultures treated with mTOR inhibitors
was accompanied by a significantly reduced overall
[methyl- 3 H]-thymidine uptake as opposed to the con-
trols, which indicates mTOR inhibitor-induced cytostasis 
(HSVEC: p  ! 0.05 for Eve; HCAEC: p  ! 0.01 for Eve and 
Sir; HMVEC: p  ! 0.05 for Eve and Sir;  fig. 1 b). Using ther-
apeutic concentrations (CsA: 0.1   M; Tac, Sir and Eve: 0.01 
  M), the impact on EC viability and proliferation de-
scribed above was confirmed.
 Impact of mTOR Inhibitors on Cell Cycle and 
Potential Apoptosis Induction 
 The inhibition of cell growth by mTOR inhibitors was 
obviously not due to an induction of programmed cell 
death, as verified via a caspase-3/7 activity assay ( fig. 2 a), 
but clearly resulted from the critical reduction in prolif-
erative activity, of about a 50% decrease in S-phase frac-
tion, determined by flow-cytometric DNA histogram 
analysis ( fig. 2 b).
 Impact of Immunosuppressive Drugs on the 
Expression of CAM 
 To elucidate the effect of immunosuppressive drugs
on the expression of CAM by EC grown to confluence, 
monolayers of EC were exposed to high concentrations
(1   M) of CsA, Tac, Sir, and Eve for 48 h. With respect to 
the anti-inflammatory activity of mTOR inhibitors (see 
above), the expression of CAM per cell was calculated. As 
shown in  figure 3 a–c, none of the CNI or mTOR inhibi-
tors affected the basal cellular expression of CAM of any 
of the studied cell types. Stimulation with TNF resulted 
in a significant increase in the expression of each CAM 
(p  ! 0.01). The increased expression of E-selectin for ex-
ample, was shown in a representative fluorescence stain-
ing in  figure 4 a. The activation of the cells with TNF was 
verified in  figures 3 d–f as the ratio of the absorbance after 
TNF stimulation and the basal absorbance. This activa-
tion factor (AF) was independent of the pretreatment 
with CNI and mTOR-inhibitors. However, under control 
conditions the AF of ICAM-1 and E-selectin were sig-
nificantly higher for HMVEC than for EC of other ori-
gins ( fig. 3 d–f).
 Impact of Immunosuppressive Drugs on the
Adhesion of Leukocytes 
 The upregulation of CAM could be verified by the ad-
hesion of PBMC to the surface of drug-treated EC. Stim-
ulation of EC with TNF resulted in an significant increase 
in the adhesion of freshly prepared PBMC as shown for 
HSVEC in  figure 4 b. While CsA and Tac did not affect 
the adhesion of PBMC to EC, incubation of EC with high 
concentrations of both mTOR inhibitors (1   M) resulted 
in a significant increase in TNF-induced PBMC adhesion 
( fig. 4 b). The other cell types provided analogous data 
(data not shown).
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 Fig. 1. Viability and growth of macro- and microvascular EC after incubation with CNI or mTOR inhibitors. 
Cell count ( a ) and incorporation of [methyl- 3 H]-thymidine per cell ( b ) were documented after 48 h. HSVEC 
(black bars, n = 10), HCAEC (light grey bars, n = 6) and HMVEC (dark grey bars, n = 4) were treated with Sir 
and Eve (1   M). Values are a percentage of the difference between mean treatment and control values (dashed
line = 100%).  * p  ! 0.05;  * * p  ! 0.01. 
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 Impact of Immunosuppressive Drugs on CAM 
Expression of EC Seeded in a Hyperconfluent 
Monolayer 
 To exclude any influence of the proliferative activity of 
untreated control cells, another set of experiments was 
repeated with a hyperconfluent monolayer known to 
auto-inhibit cell proliferation and as a result leave cell 
counts virtually unchanged. As shown in  figure 5 a, long-
term drug treatment (48 h) of nonproliferating HSVEC 
did not start an induction of E-selectin (control: 66,000 
 8 27,825 cells/cm 2 ; CsA: 77,000  8 29,300 cells/cm 2 ; Tac: 
70,400  8 28,800 cells/cm 2 ; Sir: 60,450  8 24,300 cells/
cm 2 ; Eve: 57,200  8 23,900 cells/cm 2 ; not significant). 
TNF was used as a positive control for the stimulation
of untreated control cells. In addition, preincubation of 
HSVEC with drugs (44 h) did not affect the TNF-induced 
expression of adhesion molecules. The AF was indepen-
dent of drug disposure ( fig. 5 b). The other cell types pro-
vided analogous data. According to the expression of E-
selectin, drug treatment showed no influence on the bas-
al-induced and TNF-induced expressions of ICAM-1 and 
VCAM-1 (data not shown). However, drug treatment of 
EC affected the TNF-induced adhesion of PBMC in a dif-
ferent way. While CNI did not affect the PBMC adhesion 
on HSVEC (CsA: 90  8 60%, Tac: 133  8 68% of untreat-
ed control value), preincubation of EC with mTOR in-
hibitors (1   M) resulted in an increase in the amount of 
adherent PBMC on EC (Sir: 134  8 70%, Eve: 171  8 77% 
of untreated control value). Due to the high interindivid-
ual variability of each cell culture, the differences were 
not significant. This could be detected for the other cell 
types (data not shown).
 Discussion 
 This study directly compares different immunosup-
pressive drugs under identical culture conditions regard-
ing their potential to modulate micro- and macrovascu-
lar endothelial cell properties. The essential new findings 
are that: (1) Sir and Eve inhibited proliferation of both 
macro- and microvascular EC, whereas CsA only re-
duced cell growth of coronary artery EC, and Tac showed 
generally no antiproliferative activity but exclusively re-
duced [methyl- 3 H]-thymidine incorporation of HCAEC; 
(2) none of the immunosuppressive drugs induced ex-
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pression of the investigated adhesion molecules; (3) 
mTOR inhibitors increased the TNF-induced adhesion 
of PBMC.
 In our experiments, high concentrations of CsA and 
Tac exclusively exerted antiproliferative effects on 
HCAEC in contrast to EC from other vessels. The effect 
disappeared at lower and therapeutic concentrations 
(0.1–10 n M ) of both drugs. Dose- and time-dependent re-
sponses to CNI treatment have already been described for 
diverse nonendothelial and endothelial cell types  [12–14] . 
While the cell growth of human late-outgrowth endothe-
lial progenitor cells and mature aortic EC was not affect-
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 Fig. 3. Expression of CAM on macro- and microvascular EC
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HSVEC (black bars, n = 10), HCAEC (light grey bars, n = 6) and
HMVEC (dark grey bars, n = 4) were treated with CsA, Tac, Sir, 
Eve (1   M) and the medium (control) for 48 h. The basal expres-
sion of CAM per cell ( a – c ) and the AF ( d – f ) of E-selectin ( a ,  d ), 
ICAM-1 ( b ,  e ) and VCAM-1 ( c ,  f ) were documented as mean  8 
SD. The TNF-induced expression of CAM was analyzed as the 
absorption of CAM after drug treatment and TNF incubation, 
and AF was defined as the proportion of TNF-stimulated versus 
basal absorbance. 
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ed by high concentrations of both CNI  [13, 14] , CsA re-
duced viability of EC from the blood-brain barrier  [15] 
and medullary thick ascending limb cells  [16] . In con-
trast, Tac did not affect the cell proliferation of these cell 
types  [12, 13, 15, 16] . On cellular levels, previous studies 
reported both enhanced proliferation at low concentra-
tions  [6] and decreased cell growth at high concentra-
tions  [12–14, 17, 18] . The usage of different EC types
(venous, aortic, corneal, microvascular, endothelial pro-
genitor cells or immortalized cell lines) and different in-
cubation times made a comparison of these data difficult. 
In our present study, all EC types were treated with the 
same concentration of CsA under identical culture con-
ditions. Therefore, it is conceivable that the different re-
sponses to CsA depended on the higher sensitivity of 
HCAEC for CsA. However, therapeutic concentrations of 
CsA (100–300 n M ) and of Tac (6–24 n M ) did not affect the 
cell density of drug-treated EC monolayers.
 For functional analysis, we demonstrated that none of 
the CNI exhibited an anti-inflammatory effect in our 
culture system – not even at peak concentrations. CsA 
and Tac neither affected the release of IL-6 (data not 
shown) nor the expression of CAM and the adhesion of 
PBMC. In contrast to other scientific groups, our experi-
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 Fig. 4. Expression of E-selectin and PBMC adhesion of drug-treat-
ed and untreated HSVEC.  a Immunofluorescent staining of a rep-
resentative HSVEC culture using a FITC-conjugated anti-CD62E 
antibody. Basal expression (left picture) and TNF-induced ex-
pression after 4 h (right picture) of control cells.  b HSVEC (n = 5) 
were pretreated with CsA, Tac, Sir, Eve (1   M) and the medium 
(control) for 44 h and then incubated with PBS (left picture) and 
TNF (right picture) for 4 h. Freshly prepared PBMC were incu-
bated with drug-treated and untreated EC, and the amount of 
adherent PBMC per cell was determined.  * p  ! 0.05, comparing 
drug-treated versus untreated EC. 
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mental setup should mimic steady-state conditions with 
an acute episode of TNF stimulation, as possibly seen un-
der in vivo conditions after organ transplantation. Other 
scientific groups described different effects of CsA. Char-
reau et al.  [5] and Markovic et al.  [19] showed, for exam-
ple, that CsA downregulated the expression of E-selectin 
and VCAM-1 under concomitant stimulation with TNF, 
while the expression of ICAM-1 remained unchanged 
 [19, 20] . Furthermore, Rafiee et al.  [21] demonstrated that 
CsA enhanced leukocyte binding by human intestinal 
microvascular EC (HIMEC) through inhibition of p38 
MAPK and iNOS. They used HIMEC to provide a mech-
anistic explanation regarding a proinflammatory effect 
of CsA on the organ-specific microvascular endotheli-
um, and to demonstrate the failure of this compound in 
the long-term treatment of chronic inflammatory bowel 
disease. We speculate that the different proinflammatory 
responses could be reduced to the organ-specific hetero-
geneity of EC  [8] or different culture conditions. Karlsson 
and Nassberger  [22] confirmed our finding that Tac does 
not affect EC activation in response to inflammatory 
stimuli like TNF. Moreover, up to supratherapeutic Tac 
levels, there seem to be no deleterious effects on capillar-
ies in vitro  [7] .
 In contrast, mTOR inhibitors inhibit such prolifera-
tion of both hematopoietic and nonhematopoietic cells, 
showing their action as potent immunosuppressive drugs 
 [23, 24] . Inhibition of smooth muscle cell proliferation is 
especially relevant for protection against cardiac allograft 
vasculopathy (CAV)  [25] . Moreover, one has to keep in 
mind the participation of endothelial activation/dysfunc-
tion in the process of CAV  [26] . To demonstrate the im-
pact of mTOR inhibitors on the activation status of the 
endothelial layer after transplantation or stent implanta-
tion, we documented a significant decrease in EC growth 
within the therapeutic range of immunosuppressive ef-
ficacy of Sir and Eve. Previous studies agreed with our 
data and speculated that the mechanism of cell death ap-
peared to be apoptosis induced by caspase-3 activation 
 [27–29] . However, our data, as well as those of Miriuka et 
al.  [13] , clearly showed no caspase-3 activation under 
mTOR inhibition. Instead, we observed cell-cycle arrest 
without a cytotoxic effect. We speculate that the thera-
peutic approach of mTOR inhibitors to reduce intimal 
hyperplasia by inhibition of smooth muscle cell prolif-
eration is paralleled by a reduced ability to maintain vas-
cular reendothelialization. Thus, inhibition of EC prolif-
eration by mTOR inhibitors indicates that Sir and Eve 
delay reendothelialization after balloon dilatation and 
combined introduction of drug-eluting stents, as seen in 
humans, 3 weeks after stent deployment  [13, 30, 31] .
 The central event in the development of CAV is the in-
flammatory response to immune- or non-immune-medi-
ated endothelial damage, which is also characterized by 
the upregulation of adhesion molecules and the subse-
quent binding of leukocytes  [25] . Despite the absence of 
acute inflammatory processes in heart transplant pa-
tients, the concentration of circulating adhesion mole-
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 Fig. 5. Basal and TNF-induced expression of cellular E-selectin on HSVEC after pre-incubation with different 
immunosuppressive drugs. Confluent cultures of HSVEC (n = 6) were treated with CsA, Tac, Sir, Eve (1   M) 
and the medium (control) for 48 h. The basal expression of E-selectin per cell ( a ) and the AF ( b ) were recorded 
as means  8 SD. AF was defined as the proportion of TNF-stimulated (4 h) versus basal absorbance.  a Incuba-
tion of the control cells with TNF was used as a positive control. 
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cules has been reported to be enhanced  [32] . With our 
culture system, we are able to mimic such steady-state 
conditions to evaluate the specific effects of immunosup-
pressive drugs on EC stimulation and to study the effect 
of acute inflammatory events on the activation status of 
EC. We could show that long-term incubation of micro- 
and macrovascular EC with both mTOR inhibitors had no 
effect on the basal release of IL-8 and MCP-1  [27] , as well 
as on the expression of CAM. Due to different experimen-
tal protocols in the literature  [5–7, 13, 14] , using hypercon-
fluent seeding of EC for 24 h accompanied by drug treat-
ment for an additional 24–48 h, we validated our previous 
data in a confluent monolayer experiment. The drug ef-
fects were independent of the seeding protocol. Further-
more, we recently reported on an inhibition of basal IL-6 
synthesis of HCAEC by both mTOR inhibitors  [24] , which 
could not be detected for HSVEC and HUVEC. We con-
cluded that Sir and Eve per se do not result in activation 
of the endothelium. Specific anti-inflammatory and anti-
cytokine effects of Sir were also documented in recent in 
vitro  [24, 27] and in vivo  [33] studies. In addition to that, 
the potential benefit of mTOR inhibitors, in combination 
with reduced doses of calcineurin inhibitors, was verified 
in clinical studies  [34, 35] .
 TNF stimulation of our micro- and macrovascular EC 
enhanced expression of CAM and the adhesion of leuko-
cytes. The increased density of E-selectin and VCAM-1 
on microvascular EC was also documented by Stins et al. 
 [36] . We postulate a cell type-specific heterogeneity of 
our EC  [8] . In our study, none of the mTOR inhibitors 
influenced the TNF-induced expression of CAM. Para-
doxically, the adhesion of PBMC increased significantly. 
Previous reports strengthen our data and showed that the 
TNF-induced expression of VCAM-1 was not affected by 
Eve  [37] . In contrast, Sir downregulated complement-in-
duced ICAM-1 expression in a concentration-dependent 
manner on immortalized porcine aortic EC  [38] . This 
may be due to different stimulation mechanisms compar-
ing TNF and complement, and the fact that our cells were 
not serum starved. In our cell culture system, serum star-
vation resulted in significant cell loss, whereas a high 
content of serum was essential for optimal growth of our 
patient-derived cells. It cannot be excluded, for example, 
that CNI might induce CAM after a period of serum star-
vation. However, this could not be detected in our culture 
system. The unchanged endothelial expression of CAM 
and the paradoxically increased TNF-induced leukocyte 
binding after treatment with mTOR inhibitors might be 
a result of poor sensitivity of the used assays (leukocyte 
binding assay, cellular ELISA). However, we could vali-
date our cellular ELISA data with flow-cytometric analy-
sis (data not shown). A similar situation was described by 
Rafiee et al.  [21] . CsA enhances leukocyte binding by 
HIMEC leaving CAM expression of these microvascular 
EC unaffected. Obviously, other factors like elevated 
Lp(a) levels can lead to monocyte recruitment via Mac-1 
integrin interaction  [39] , an effect which is widely inde-
pendent of CAM activation. Additional experiments are 
necessary to study the complex network of endothelial 
dysfunction after drug treatment.
 In summary, treatment of EC with mTOR inhibitors 
delayed reendothelialization in a dose-dependent man-
ner  [24] . However, our data also show that neither calci-
neurin inhibitors nor mTOR-inhibitors activated EC per 
se. This suggests that the chronic inflammatory process 
after transplantation  [32] is not triggered by the specific 
effects of immunosuppressive drugs on the EC monolay-
er. Anti-inflammatory effects of mTOR-inhibitors may 
also be beneficial in future clinical trials by allowing a 
withdrawal or dose-reduction of CNI in the immunosup-
pressive regimen after cardiac transplantation.
 Acknowledgments 
 The authors gratefully acknowledge the excellent technical as-
sistance of A. Urbanek, S. Bergman, C. Leykauf, K. Bielenberg, K. 
Hollnberger and M. Wondrak. The project was supported by No-
vartis-Pharma GmbH (Nürnberg, Germany).
 
 References 
 1 Weis M, von Scheidt W: Cardiac allograft 
vasculopathy: a review. Circulation 1997; 96: 
 2069–2077. 
 2 Wu YW, Lee CM, Lee YT, Wang SS, Huang 
PJ: Value of circulating adhesion molecules 
in assessing cardiac allograft vasculopathy. J 
Heart Lung Transplant 2003; 22: 1284–1287. 
 3 Olyaei AJ, de Mattos AM, Bennett WM: 
Nephrotoxicity of immunosuppressive 
drugs: new insight and preventive strategies. 
Curr Opin Crit Care 2001; 7: 384–389. 
 4 Weis M, Wildhirt SM, Schulze C, Pehlivanli 
S, Rieder G, Wolf WP, Wilbert-Lampen U, 
Meiser BM, Enders G, von Scheidt W: Coro-
nary vasomotor dysfunction in the cariac al-
lograft: impact of different immunosuppres-
sive regimens. J Cardiovasc Pharmacol 2000; 
 36: 776–784. 
 5 Charreau B, Coupel S, Goret F, Pourcel C, 
Soulillou JP: Association of glucocorticoids 
and cyclosporin A or rapamycin prevents E-
selectin and IL-8 expression during LPS- 
and TNF-mediated endothelial cell activa-
tion. Transplantation 2000; 69: 945–953. 
 6 Trapp A, Weis M: The impact of immuno-
suppression on endothelial function. J Car-
diovasc Pharmacol 2005; 45: 81–87. 
 Lehle /Schreml /Kunz-Schughart /
Rupprecht /Birnbaum /Schmid /Preuner 
J Vasc Res 2008;45:333–342342
 28 Riesterer O, Zingg D, Hummerjohann J, 
Bodis S, Pruschy M: Degradation of PKB/
Akt protein by inhibition of the VEGF recep-
tor/mTOR pathway in endothelial cells. On-
cogene 2004; 23: 4624–4635. 
 29 Sugatani T, Hruska KA: Akt1/Akt2 and 
mammalian target of rapamycin/Bim play 
critical roles in osteoclast differentiation and 
survival, respectively, whereas Akt is dis-
pensable for cell survival in isolated osteo-
clast precursors. J Biol Chem 2005;  280: 
 3583–3589. 
 30 Farb A, Sangiorgi G, Carter AJ, Walley VM, 
Edwards WD, Schwartz RS, Virmani R: Pa-
thology of acute and chronic coronary stent-
ing in humans. Circulation 1999; 99: 44–52. 
 31 Grewe PH, Deneke T, Machraoui A, Barmey-
er J, Muller KM: Acute and chronic tissue
response to coronary stent implantation: 
pathologic findings in human specimen. J 
Am Coll Cardiol 2000; 35: 157–163. 
 32 Wildhirt SM, Schulze C, Conrad N, Bauern-
schmitt R, Lange R, von Scheidt W: Persis-
tently increased systemic, but not cardiac-
specific, adhesion molecule expression and 
coronary endothelial dysfunction in hu-
man cardiac allografts. J Thorac Cardiovasc 
Surg 2005; 130: 1175. 
 33 Schmid C, Heemann U, Azuma H, Tilney 
NL: Rapamycin inhibits transplant vascu-
lopathy in long-surviving rat heart allo-
grafts. Transplantation 1995; 60: 729–733. 
 34 Bestard O, Cruzado JM, Grinyo JM: Calci-
neurin-inhibitor-sparing immunosuppres-
sive protocols. Transplant Proc 2005;  37: 
 3729–3732. 
 35 Merville P: Combating chronic renal al-
lograft dysfunction: optimal immunosup-
pressive regimens. Drugs 2005; 65: 615–631. 
 36 Stins MF, Gilles F, Kim KS: Selective expres-
sion of adhesion molecules on human brain 
microvascular endothelial cells. J Neuroim-
munol 1997; 76: 81–90. 
 37 Haubitz M, Brunkhorst M: Influence of a 
novel rapamycin analogon SDZ RAD on en-
dothelial tissue factor and adhesion mole-
cule expression. Transplant Proc 2002; 34: 
 1124–1126. 
 38 Wood SC, Bushar G, Tesfamariam B: Inhibi-
tion of mammalian target of rapamycin 
modulates expression of adhesion molecules 
in endothelial cells. Toxicol Lett 2006; 165: 
 242–249. 
 39 Sotiriou SN, Orlova VV, Al-Fakhri N, Ihanus 
E, Economopoulou M, Isermann B, Bdeir K, 
Nawroth PP, Preissner KT, Gahmberg CG, 
Koschinsky ML, Chavakis T: Lipoprotein(a) 
in atherosclerotic plaques recruits inflam-
matory cells through interaction with Mac-1 
integrin. FASEB J 2006; 20: 559–561. 
 
 7 Wilasrusmee C, Da Silva M, Singh B, Sid-
diqui J, Bruch D, Kittur S, Wilasrusmee S, 
Kittur DS: Morphological and biochemical 
effects of immunosuppressive drugs in a cap-
illary tube assay for endothelial dysfunction. 
Clin Transplant 2003; 17: 6–12. 
 8 Aird WC: Spatial and temporal dynamics of 
the endothelium. J Thromb Haemost 2005; 3: 
 1392–1406. 
 9 Ribatti D, Nico B, Vacca A, Roncali L, Dam-
macco F: Endothelial cell heterogeneity and 
organ specificity. J Heamatother Stem Cell 
Res 2002; 11: 81–90. 
 10 Lehle K, Buttstaedt J, Birnbaum DE: Expres-
sion of adhesion molecules and cytokines in 
vitro by endothelial cells seeded on various 
polymer surfaces coated with titaniumcar-
boxonitride. J Biomed Mater Res 2003; 65: 
 393–401. 
 11 De Clerck LS, Bridts CH, Mertens AM, 
Moens MM, Stevens WJ: Use of f luorescent 
dyes in the determination of adherence of 
human leucocytes to endothelial cells and 
the effect of f luorochromes on cellular func-
tion. J Immunol Methods 1994; 172: 115–
124. 
 12 Esposito C, Fornoni A, Cornacchia F, Bel-
lotti N, Fasoli G, Foschi A, Mazzucchelli I, 
Mazzullo T, Semeraro L, Dal Canton A: Cy-
closporine induces different responses in 
human epithelial, endothelial and fibroblast 
cell cultures. Kidney Int 2000; 58: 123–130. 
 13 Miriuka SG, Rao V, Peterson M, Tumiati L, 
Delgado DH, Mohan R, Ramzy D, Stewart D, 
Ross HJ, Waddell TK: mTOR inhibition in-
duces endothelial progenitor cell death. Am 
J Transplant 2006; 6: 2069–2079. 
 14 Mohacsi PJ, Tuller D, Hulliger B, Wijngaard 
PL: Different inhibitory effects of immuno-
suppressive drugs on human and rat aor-
tic smooth muscle and endothelial cell pro-
liferation stimulated by platelet-derived 
growth factor or endothelial cell growth fac-
tor. J Heart Lung Transplant 1997; 16: 484–
492. 
 15 Kochi S, Takanaga H, Matsuo H, Naito M, 
Tsuruo T, Sawada Y: Effect of cyclosporin A 
or tacrolimus on the function of blood-brain 
barrier cells. Eur J Pharmacol 1999; 372: 287–
295. 
 16 Wu MS, Yu HM, Hong JJ, Lai BC, Huang CC, 
Vandewalle A: Cyclosporine, but not FK 506 
and rapamycin, enhances cell proliferation 
in mouse medullary thick ascending cul-
tured cells. Transplant Proc 1998; 30: 3565–
3566. 
 17 Garweg JG, Wegmann-Burns M, Goldblum 
D: Effects of daunorubicin, mitomycin C, 
azathioprine and cyclosporin A on human 
retinal pigmented epithelial, corneal endo-
thelial and conjunctival cell lines. Graefes 
Arch Clin Exp Ophthalmol 2006; 244: 382–
389. 
 18 Seki Y, Toba K, Fuse I, Sato N, Niwano H, 
Takahashi H, Tanabe N, Aizawa Y: In vitro 
effect of cyclosporin A, mitomycin C and 
prednisolone on cell kinetics in cultured
human umbilical vein endothelial cells. 
Thromb Res 2005; 115: 219–228. 
 19 Markovic S, Raab M, Daxecker H, Griesma-
cher A, Karimi A, Müller MM: In vitro ef-
fects of cyclosporin A on the expression of 
adhesion molecules on human umbilical 
vein endothelial cells. Clin Chim Acta 2002; 
 316: 25–31. 
 20 Maksymowicz M, Lukomska B, Ziolkowska 
A, Janczewska S, Cybulska E, Olszewski WL: 
Cyclosporin A decreases lymphocyte migra-
tion to the heart allograft through suppres-
sion of their L-selectin expression. Ann 
Transplant 1998; 3: 34–36. 
 21 Rafiee P, Johnson CP, Li MS, Ogawa H, 
Heidemann J, Fisher PJ, Lamirand TH, Ot-
terson MF, Wilson KT, Binion DG: Cyclo-
sporine A enhances leukocyte binding by 
human intestinal microvascular endothelial 
cells through inhibition of p38 MAPK and 
iNOS: paradoxical proinflammatory effect 
on the microvascular endothelium. J Biol 
Chem 2002; 277: 35605–35615. 
 22 Karlsson H, Nassberger L: FK506 suppresses 
the mitogen-induced increase in lymphocyte 
adhesiveness to endothelial cells, but does 
not affect endothelial cell activation in re-
sponse to inflammatory stimuli. Transplan-
tation 1997; 64: 1217–1220. 
 23 Mancini D, Pinney S, Burkhoff D, LaManca 
J, Itescu S, Burke E, Edwards N, Oz M, Marks 
AR: Use of rapamycin slows progression of 
cardiac transplantation vasculopathy. Cir-
culation 2003; 108: 48–53. 
 24 Schreml S, Lehle K, Birnbaum DE, Preuner 
JG: mTOR-inhibitors simultaneously inhibit 
proliferation and basal IL-6 synthesis of hu-
man coronary artery endothelial cells. Int 
Immunopharmacol 2007; 7: 781–791. 
 25 Pinney SP, Mancini D: Cardiac allograft vas-
culopathy: advances in understanding its 
pathophysiology, prevention, and treatment. 
Curr Opin Cardiol 2004; 19: 170–176. 
 26 Valantine HA: Cardiac allograft vasculopa-
thy: central role of endothelial injury leading 
to transplant ‘atheroma’. Transplantation 
2003; 76: 891–899. 
 27 Lehle K, Birnbaum DE, Preuner JG: Predom-
inant inhibition of interleukin-6 synthesis in 
patient-specific endothelial cells by mTOR 
inhibitors below a concentration range where 
cell proliferation is affected and mitotic ar-
rest takes place. Transplant Proc 2005; 37: 
 159–161. 
